Answers are grounded in this paper and cite their sources.
Analytical method quantifies bexicaserin in human cerebrospinal fluid, suggesting its utility in clinical research.
Bexicaserin is an investigational molecule that is a highly selective superagonist of the 5‐hydroxytryptamine 2C (5HT 2c ) serotonin receptor subtype and in Phase 3 clinical studies for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs). We have validated a simple LC–MS/MS method for the quantitative estimation of bexicaserin in human cerebrospinal fluid (CSF). The chromatographic separation of bexicaserin and the IS was achieved on an Acquity HSS T3, C18 column using a 5.5‐min gradient program. The sample preparation involves the dilution extraction of bexicaserin and the isotope labeled internal standard ( 13 CD 2 ‐bexicaserin; IS) from 25 μL of human CSF. The calibration curve was linear from a range of 0.1–100 ng/mL. The method was fully validated as per the regulatory guidelines. The intraday and interday precision for bexicaserin was in the range of 6.3%–8.7% and 6.0%–8.8%. Bexicaserin intraday and interday bias was in the range of −15.1% (LLOQ) to 12.0% and −10.0% to 1.2%. Stability studies showed that bexicaserin was stable on bench for 24 h, in autosampler for over 50 h, and extract stability at 6 ° C for 76 h. Bexicaserin was stable after five freeze–thaw cycles and long‐term storage at −20°C for 108 days and −80 ° C for 102 days.
No takes yet. Share an insight, caveat, or question.
Kallem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: